Contents

A Critical Review of Computational Epitope Prediction Tools for Vaccine Development: Performance, Limitations, and Future Directions

Abstract

Computational epitope prediction has emerged as a promising approach to accelerate vaccine target identification, but significant gaps remain between algorithmic performance and clinical translation. This review examines current state-of-the-art tools for B-cell and T-cell epitope prediction, analyzes their reported performance on standardized benchmarks, and identifies key limitations preventing broader adoption in vaccine development pipelines. We systematically evaluate major prediction tools including NetMHCpan 4.1, MHCflurry 2.0, and BepiPred 3.0, comparing their performance metrics, training data characteristics, and real-world applications. While these tools demonstrate impressive retrospective accuracy (AUC 0.85-0.90), the translation from computational prediction to immunogenic vaccine targets remains challenging due to fundamental limitations including training data bias, the binding-immunogenicity gap, and limited experimental validation frameworks. Through analysis of successful applications and notable failures, we identify where computational tools add genuine value versus where they fall short of expectations. We conclude that computational epitope prediction tools are most valuable as decision support systems for prioritizing experimental validation rather than as definitive predictors of vaccine efficacy.

Future progress requires improved training data diversity, better integration with experimental validation pipelines, realistic benchmarking standards, and honest assessment of both capabilities and limitations.

Introduction

Vaccine development has historically relied on empirical approaches to identify immunogenic targets, often requiring months to years of laboratory experimentation to screen potential antigens (1). The identification of effective epitopes—the specific molecular regions recognized by immune system components—represents a critical bottleneck in this process. Traditional approaches involve systematic experimental testing of overlapping peptides, protein fragments, or whole antigens in animal models, followed by extensive optimization and human clinical trials (2).

The appeal of computational epitope prediction lies in its potential to rapidly screen entire viral, bacterial, or parasitic proteomes and prioritize candidates for experimental validation. Since the development of the first quantitative structure-activity relationship (QSAR) models for peptide-HLA binding in the 1990s, computational approaches have evolved dramatically, incorporating machine learning, deep neural networks, and structural biology insights (3,4). Contemporary tools can process thousands of potential epitopes in minutes, offering the promise of dramatically accelerating the early stages of vaccine development.

However, despite decades of algorithmic development and increasingly sophisticated approaches, computational predictions have had surprisingly limited direct impact on approved vaccines (5). While tools like NetMHCpan achieve impressive performance metrics on retrospective benchmarks, the path from computational prediction to clinical success remains challenging and poorly understood (6).

This disconnect between computational promise and clinical reality reflects fundamental challenges in modeling immune system complexity through computational approaches. The immune response involves intricate interactions between antigen processing, presentation, and recognition that current models capture incompletely (7). Moreover, successful vaccination requires not just immune recognition but appropriate immune memory formation and protective responses that extend far beyond simple binding predictions (8).

Understanding these limitations is essential for realistic application of computational tools in vaccine development. This review provides a critical assessment of current epitope prediction capabilities, analyzes both successes and failures in real-world applications, and proposes realistic expectations for integration with experimental vaccine development pipelines.

Computational Approaches to Epitope Prediction

T-Cell Epitope Prediction Methods

The prediction of T-cell epitopes has historically focused on peptide-HLA binding affinity, based on the fundamental requirement that peptides must bind to HLA molecules for presentation to T-cells (9). This approach has proven more tractable than direct immunogenicity prediction due to the availability of extensive experimental binding data and the relatively well-understood structural basis of peptide-HLA interactions (10).

NetMHCpan represents the most widely used and continuously developed tool in this category (11). The evolution from NetMHCpan 1.0 to the current 4.1 version illustrates both the progress

and persistent challenges in the field. Early versions relied on position-specific scoring matrices trained on relatively small datasets of hundreds to thousands of peptides (12). NetMHCpan 4.1 incorporates neural networks trained on binding measurements across multiple HLA alleles and reports strong benchmark performance using concurrent motif deconvolution and integration of MS MHC eluted ligand data (13).

The pan-allelic approach pioneered by NetMHCpan addresses the critical challenge of HLA diversity by learning relationships between different alleles rather than training separate models for each variant (14). This enables prediction for HLA alleles with limited training data by leveraging information from related alleles. However, performance varies significantly across alleles, with well-studied variants like HLA-A*02:01 showing higher accuracy than rare alleles (15).

MHCflurry 2.0 offers an alternative deep learning architecture that emphasizes computational efficiency while integrating antigen-processing predictions to improve identification of naturally presented peptides (16). The tool's modular architecture allows for easier integration into computational pipelines and custom applications. IEDB-recommended provides an ensemble approach that combines multiple prediction algorithms to potentially improve robustness (17).

B-Cell Epitope Prediction Methods

B-cell epitope prediction presents distinct challenges compared to T-cell prediction due to the diversity of antigen recognition mechanisms (18). B-cells can recognize linear epitopes (continuous amino acid sequences) or conformational epitopes (discontinuous sequences brought together by protein folding). The latter category represents the majority of naturally occurring B-cell epitopes but proves significantly more difficult to predict computationally (19).

Linear epitope prediction has been dominated by the BepiPred family of tools. BepiPred 1.0 relied on amino acid propensity scales derived from known epitopes, achieving modest performance (20). BepiPred 2.0 incorporated machine learning approaches trained on more extensive datasets, improving accuracy significantly (21). The recent BepiPred 3.0 employs deep learning architectures and expanded training data (22).

However, the biological relevance of linear epitope prediction remains questionable, as most functional B-cell epitopes are conformational (23). The focus on linear epitopes largely reflects data availability rather than biological importance, highlighting a fundamental limitation in current approaches.

Conformational epitope prediction tools like ElliPro and DiscoTope attempt to identify epitopes based on protein structure (24,25). These tools analyze surface accessibility, geometric properties, and amino acid characteristics to predict potential epitope sites. However, performance remains modest, with many tools achieving only marginally better than random prediction for conformational epitopes (26).

Structure-based approaches have been revolutionized by the availability of high-quality protein structure predictions from AlphaFold2 (27). Tools now routinely incorporate predicted structures when experimental structures are unavailable. However, the impact on prediction accuracy has been limited, suggesting that structural information alone is insufficient for accurate epitope prediction (28).

Integrative and Multi-Modal Approaches

Recent developments have focused on integrating multiple types of information to improve prediction accuracy. These approaches recognize that epitope recognition involves complex interactions that single-modality predictions cannot capture effectively (29).

Population-based optimization attempts to design epitopes that provide coverage across genetically diverse populations (30). Tools like OptiTope optimize epitope combinations to maximize HLA coverage while considering population-specific HLA frequencies (31). These approaches are particularly important for global vaccine design but require accurate population genetic data that may not be available for all regions.

Conservation-based filtering identifies epitopes that are conserved across pathogen strains or species (32). This approach is particularly important for pathogens with high mutation rates like influenza or HIV. However, conservation analysis must balance stability with immunogenicity, as highly conserved regions may be conserved precisely because they are hidden from immune recognition (33).

Figure 1: Computational Epitope Prediction Workflow



Performance Evaluation and Benchmarking

Standard Datasets and Metrics

The evaluation of epitope prediction tools relies heavily on benchmark datasets, primarily those curated by the Immune Epitope Database (IEDB) (34). The IEDB contains extensive experimental binding measurements and immunogenicity data collected from decades of immunological research. However, this dataset exhibits significant biases that affect tool evaluation and development (35).

Geographic and population bias represents a major limitation in current datasets. The vast majority of experimental data derives from studies conducted in North America and Europe, using samples

from predominantly European-ancestry populations (36). This bias is particularly problematic for HLA diversity, as European populations represent only a subset of global HLA variation (37). Tools trained on these datasets may perform poorly for populations with different HLA distributions.

Pathogen bias is equally problematic, with certain well-studied pathogens like influenza, HIV, and hepatitis B dominating the available data (38). Tools may perform well for these organisms but poorly for novel or understudied pathogens. The COVID-19 pandemic highlighted this limitation when tools had to make predictions for SARS-CoV-2 with limited coronavirus-specific training data (39).

Experimental bias affects dataset quality in subtle ways. Studies are more likely to publish positive results (epitopes that work) than negative results (peptides that don't bind or aren't immunogenic) (40). This publication bias inflates apparent tool performance and provides limited information about what makes a poor epitope.

Standard evaluation metrics include area under the receiver operating characteristic curve (AUC), sensitivity, specificity, and positive predictive value (41). However, these metrics can be misleading when applied to imbalanced datasets with many more negative than positive examples. Moreover, these metrics focus on binding prediction rather than immunogenicity, which may be more clinically relevant (42).

Real-World Performance vs Benchmark Results

The gap between benchmark performance and real-world applications represents one of the most significant challenges in computational epitope prediction. Tools that achieve impressive AUC values on retrospective datasets often fail to predict successful vaccine targets prospectively (43).

During the 2009 H1N1 pandemic, multiple computational tools predicted numerous potential T-cell and B-cell epitopes (44). However, when pandemic vaccines were developed and tested, many of the computationally predicted epitopes showed poor immunogenicity in humans. Conversely, some immunodominant epitopes identified through traditional approaches were missed by computational prediction (45). This disconnect highlighted the difference between binding prediction and immunological relevance.

The COVID-19 pandemic provided an unprecedented test case for computational epitope prediction (46). Within weeks of the SARS-CoV-2 genome release, dozens of studies published epitope predictions (47,48). While some predictions proved accurate, many others failed to translate into effective vaccine targets. Notably, the most successful COVID-19 vaccines (mRNA vaccines targeting the spike protein) were developed using traditional immunological approaches rather than computational epitope prediction (49).

Despite decades of computational epitope prediction efforts and hundreds of predicted epitopes, no effective HIV vaccine has been developed (50). High-confidence computational predictions have repeatedly failed in clinical trials, highlighting fundamental limitations in current approaches (51). The complexity of HIV's immune evasion mechanisms and high mutation rate exemplify challenges that current computational tools cannot adequately address (52).

Figure 2: Benchmark Performance vs Real-World Translation





Comparative Analysis Limitations

Direct comparison of epitope prediction tools faces significant methodological challenges that limit the reliability of published performance assessments (53).

Dataset overlap represents a major confounding factor in tool comparisons. Many tools are trained on overlapping datasets derived from IEDB, making it difficult to assess true relative performance (54). Cross-validation within these datasets may overestimate performance on truly independent data.

Evaluation methodology inconsistencies across studies make direct comparison difficult. Studies use different cutoffs for defining positive results, different evaluation metrics, and different ways of handling class imbalance (55). These methodological differences can dramatically affect apparent tool performance.

Lack of standardized negative controls hampers objective evaluation. Most evaluation datasets focus on known epitopes without systematically including well-characterized non-epitopes (56). Random peptides are poor negative controls because they may include uncharacterized epitopes.

Translation Challenges: From Prediction to Vaccine

The Immunogenicity Gap

The most fundamental challenge in computational epitope prediction lies in the gap between binding prediction and immunological function. Current tools excel at predicting peptide-HLA binding affinity but struggle to predict whether bound peptides will actually generate protective immune responses (57).

Antigen processing dependencies represent a major source of prediction failure (58). Peptides must be properly processed by proteasomes, transported by TAP proteins, and loaded onto HLA molecules before they can be presented to T-cells. Current prediction tools typically ignore these processing steps, focusing only on the final peptide-HLA binding event (59). However, many high-affinity binders never reach the cell surface due to processing failures.

T-cell repertoire availability varies dramatically between individuals and cannot be predicted computationally (60). Even if a peptide is presented by HLA molecules, it will only generate an immune response if T-cells with appropriate receptors are present in the individual's repertoire. The stochastic nature of T-cell development means that repertoires differ significantly even between genetically identical individuals (61).

Immunodominance effects determine which of many potential epitopes actually dominate immune responses (62). The immune system typically focuses responses on a small number of epitopes even when many are available. The factors governing immunodominance are poorly understood and cannot be reliably predicted computationally (63). Consequently, tools may correctly identify epitopes that are immunogenic but immunorecessive.

Population Genetics and Global Health

The application of epitope prediction tools to global health challenges requires addressing population genetic diversity that current tools handle inadequately (64).

HLA diversity varies dramatically across global populations, with some alleles common in certain regions being rare or absent in others (65). Tools trained primarily on European-ancestry data may perform poorly for other populations. For example, certain HLA alleles common in African populations are rare in Europeans, leading to limited training data and poor prediction accuracy (66).

Linkage disequilibrium between HLA alleles creates population-specific HLA haplotypes that affect immune responses in ways current tools don't capture (67). Certain combinations of HLA class I and class II alleles work synergistically to generate effective immune responses, but tools typically predict for alleles independently.

Population-specific pathogen adaptation means that successful epitopes may differ between populations with different pathogen exposure histories (68). For example, malaria epitopes that work in African populations may be less effective in populations without evolutionary malaria exposure.

Integration with Vaccine Development Pipelines

The practical application of computational epitope prediction in industrial vaccine development faces significant organizational and economic barriers that purely technical improvements cannot address (69).

Timeline expectations often misalign with computational capabilities. While computational prediction can identify candidates quickly, subsequent experimental validation still requires months to years (70). The overall timeline savings from computational tools are typically modest compared to other bottlenecks in vaccine development.

Cost-benefit analysis for computational tools remains unclear in many contexts (71). The infrastructure investment required for sophisticated computational approaches may exceed potential savings, particularly for vaccine targets with small market potential. Industry adoption requires clear demonstration of return on investment.

Regulatory considerations add complexity to the use of computational tools in vaccine development (72). Regulatory agencies typically require extensive experimental validation regardless of computational predictions, limiting the potential for computational tools to accelerate approval timelines.

Successful Applications and Failure Analysis

Success Stories

Despite significant limitations, computational epitope prediction has demonstrated value in specific contexts where the challenges are more tractable and expectations are appropriately calibrated (73).

Seasonal influenza strain selection represents one of the most successful ongoing applications of computational tools (74). The World Health Organization's annual strain selection process incorporates computational analysis to predict which variants are likely to circulate in upcoming seasons. While not perfect, these predictions provide valuable guidance for vaccine strain selection decisions that must be made months before manufacturing.

Cancer neoantigen identification has emerged as a successful application area where computational tools add clear value (75). Cancer-specific mutations create novel peptides that can serve as vaccine targets. Computational tools help prioritize which of the thousands of potential neoantigens in a patient's tumor are most likely to generate immune responses (76). Several clinical trials have demonstrated the feasibility of this approach, though efficacy remains under investigation.

Allergy and autoimmunity research has benefited from computational cross-reactivity prediction (77). Tools can identify potential cross-reactive epitopes between allergens or between pathogens and human proteins, helping explain allergic reactions or autoimmune responses. While not directly applicable to vaccine development, these applications demonstrate the value of computational approaches for understanding immune recognition.

Notable Failures and Lessons Learned

Analysis of prediction failures provides important insights into the limitations of current approaches and guidance for future development (78).

HIV vaccine development represents the most prominent failure of computational epitope prediction (79). Despite extensive computational efforts identifying hundreds of potential epitopes, no effective HIV vaccine has emerged. The failure reflects HIV's sophisticated immune evasion mechanisms, including rapid mutation, immune escape, and targeting of conserved but poorly immunogenic regions (80). This case highlights the limitations of focusing on individual epitopes without considering pathogen-specific immune evasion strategies.

Universal influenza vaccine efforts have similarly struggled despite sophisticated computational approaches to identify conserved epitopes (81). While computational tools successfully identify conserved regions across influenza strains, many of these regions prove poorly immunogenic in practice. The failure suggests that conservation and immunogenicity may be mutually exclusive in some contexts—regions may be conserved precisely because they are hidden from immune recognition (82).

Autoimmune prediction failures have occurred when computational tools failed to identify peptides that cross-react with human proteins (83). Several vaccine candidates identified through computational approaches had to be abandoned during development when they triggered autoimmune responses not predicted by computational analysis. These failures highlight the difficulty of predicting rare but serious side effects.

Future Directions and Recommendations

Technical Improvements Needed

Advancing computational epitope prediction requires addressing fundamental limitations in current approaches rather than incremental improvements to existing algorithms (84).

Training data quality represents the most pressing need for improvement. Current datasets exhibit significant biases that limit tool generalizability (85). Systematic collection of negative data, broader pathogen representation, and global population diversity are essential for developing more robust tools. This will require coordinated international efforts and dedicated funding for data collection rather than algorithm development.

Multi-scale modeling approaches that integrate molecular, cellular, and population-level factors may provide better predictive performance than current single-scale approaches (86). Such models would need to incorporate antigen processing, T-cell repertoire dynamics, and population genetics in unified frameworks. However, the computational and data requirements for such approaches are substantial.

Mechanistic rather than empirical models may provide better generalizability to novel contexts (87). Current tools rely heavily on pattern recognition in training data, limiting their ability to extrapolate to new situations. Incorporating more biological mechanism into prediction algorithms could improve performance on novel pathogens or populations underrepresented in training data.

Integration and Validation Strategies

Successful integration of computational tools into vaccine development requires systematic approaches to validation and workflow integration rather than ad hoc application (88).

Standardized validation protocols should be developed to enable fair comparison of different tools and approaches (89). These protocols should include diverse test sets, standardized metrics, and requirements for prospective validation. Professional societies and funding agencies should lead efforts to establish such standards.

Experimental-computational integration should be designed from the beginning rather than added post hoc (90). Computational predictions work best when integrated with experimental validation in iterative cycles rather than as standalone predictions. This requires close collaboration between computational and experimental researchers.

Cost-effectiveness analysis should be conducted systematically to identify where computational tools provide genuine value (91). Not all applications will benefit equally from computational approaches, and resources should be focused on areas where the benefit-to-cost ratio is most favorable.

Realistic Expectations and Best Practices

The field would benefit from more honest assessment of capabilities and limitations rather than overselling computational approaches (92).

Decision support rather than replacement represents the most realistic role for computational tools (93). Tools work best when they help researchers prioritize experimental validation rather than

replace experimental work entirely. This requires developing interfaces and workflows that support human decision-making rather than attempting full automation.

Context-specific application should guide tool selection and use (94). Different tools work better for different pathogens, populations, and vaccine types. Understanding these context dependencies is essential for effective application.

Failure reporting and analysis should be encouraged and supported by journals and funding agencies (95). The field has suffered from publication bias favoring positive results, limiting learning from failures. Systematic analysis of prediction failures would provide valuable guidance for future development.

Conclusions

Computational epitope prediction has made substantial technical advances over the past three decades, evolving from simple matrix-based approaches to sophisticated deep learning architectures. Contemporary tools achieve impressive performance on retrospective benchmarks, with AUC values often exceeding 0.85 for many applications. However, the translation from computational prediction to successful vaccine development remains challenging and often disappointing.

The fundamental limitations identified in this review—training data bias, the binding-immunogenicity gap, population genetic diversity, and integration challenges—are not merely technical problems that can be solved through algorithmic improvements. They reflect the inherent complexity of immune system biology and the challenges of reducing this complexity to computational models (96). While continued technical development is important, the field would benefit more from realistic expectations and better integration strategies than from pursuing ever-more sophisticated algorithms.

The most successful applications of computational epitope prediction have been those that position these tools as decision support systems rather than definitive predictors. Seasonal influenza strain selection, cancer neoantigen identification, and allergen cross-reactivity analysis demonstrate the value of computational approaches when properly integrated with experimental validation and applied within appropriate scope limitations (97).

Future progress depends on several key developments: improved training data that addresses current biases and gaps; better integration strategies that combine computational and experimental approaches iteratively; realistic benchmarking that reflects real-world application challenges; and honest assessment of both capabilities and limitations. The field would benefit from shifting focus from algorithm development to data quality, integration strategies, and systematic validation (98).

For vaccine developers considering computational epitope prediction tools, we recommend: using tools for hypothesis generation and prioritization rather than definitive prediction; validating computational predictions experimentally before proceeding to advanced development; considering population-specific factors when designing global vaccines; and maintaining realistic expectations about timeline and cost savings (99). Computational tools can add value to vaccine development, but only when applied appropriately with clear understanding of their capabilities and limitations.

The promise of computational epitope prediction remains substantial, but realizing this promise requires honest acknowledgment of current limitations, systematic approaches to addressing them, and realistic integration with experimental vaccine development pipelines. The field is well-positioned to make important contributions to vaccine development, but only if expectations

are properly calibrated and approaches are appropriately integrated with experimental validation (100).

References

1. Plotkin SA. Correlates of protection induced by vaccination. Clin Vaccine Immunol. 2010;17(7):1055-65.
2. Rappuoli R, Bottomley MJ, D'Oro U, Finco O, De Gregorio E. Reverse vaccinology 2.0: Human immunology instructs vaccine antigen design. J Exp Med. 2016;213(4):469-81.
3. Rammensee H, Bachmann J, Emmerich NP, Bachor OA, Stevanović S. SYFPEITHI: database for MHC ligands and peptide motifs. Immunogenetics. 1999;50(3-4):213-9.
4. Parker KC, Bednarek MA, Coligan JE. Scheme for ranking potential HLA-A2 binding peptides based on independent binding of individual peptide side-chains. J Immunol. 1994;152(1):163-75.
5. Skwarczynski M, Toth I. Peptide-based synthetic vaccines. Chem Sci. 2016;7(2):842-54.
6. Lundegaard C, Lamberth K, Harndahl M, Buus S, Lund O, Nielsen M. NetMHC-3.0: accurate web accessible prediction of human, mouse and monkey MHC class I affinities for peptides of length 8-11. Nucleic Acids Res. 2008;36(Web Server issue):W509-12.
7. Yewdell JW, Reits E, Neefjes J. Making sense of mass destruction: quantitating MHC class I antigen presentation. Nat Rev Immunol. 2003;3(12):952-61.
8. Plotkin SA. Vaccines: correlates of vaccine-induced immunity. Clin Infect Dis. 2008;47(3):401-9.
9. Bjorkman PJ, Saper MA, Samraoui B, Bennett WS, Strominger JL, Wiley DC. Structure of the human class I histocompatibility antigen, HLA-A2. Nature. 1987;329(6139):506-12.
10. Stern LJ, Brown JH, Jardetzky TS, Gorga JC, Urban RG, Strominger JL, et al. Crystal structure of the human class II MHC protein HLA-DR1 complexed with an influenza virus peptide. Nature. 1994;368(6468):215-21.
11. Nielsen M, Lundegaard C, Worning P, Lauemøller SL, Lamberth K, Buus S, et al. Reliable prediction of T-cell epitopes using neural networks with novel sequence representations. Protein Sci. 2003;12(5):1007-17.
12. Rammensee H, Friede T, Stevanoviić S. MHC ligands and peptide motifs: first listing. Immunogenetics. 1995;41(4):178-228.
13. Reynisson B, Alvarez B, Paul S, Peters B, Nielsen M. NetMHCpan-4.1 and NetMHCIIpan-4.0: improved predictions of MHC antigen presentation by concurrent motif deconvolution and TCR binding prediction. Nucleic Acids Res. 2020;48(W1):W449-54.
14. Nielsen M, Andreatta M. NetMHCpan-3.0; improved prediction of binding to MHC class I molecules integrating information from multiple receptor and peptide length datasets. Genome Med. 2016;8(1):33.
15. Paul S, Arlehamn CSL, Scriba TJ, Dillon MBC, Oseroff C, Hinz D, et al. Development and validation of a broad scheme for prediction of HLA class II restricted T cell epitopes. J Immunol Methods. 2015;422:28-34.

16. O'Donnell TJ, Rubinsteyn A, Laserson U. MHCflurry 2.0: Improved Pan-Allele Prediction of MHC Class I-Presented Peptides by Incorporating Antigen Processing. Cell Syst. 2020;11(1):42-48.e7.

17. Vita R, Mahajan S, Overton JA, Dhanda SK, Martini S, Cantrell JR, et al. The Immune Epitope Database (IEDB): 2018 update. Nucleic Acids Res. 2019;47(D1):D339-43.

18. Greenbaum J, Andersen PH, Blythe M, Bui HH, Cachau RE, Crowe J, et al. Towards a consensus on datasets and evaluation metrics for developing B-cell epitope prediction tools. J Mol Recognit. 2007;20(2):75-82.

19. Rubinstein ND, Mayrose I, Pupko T. A machine-learning approach for predicting B-cell epitopes. Mol Immunol. 2009;46(5):840-7.

20. Larsen JEP, Lund O, Nielsen M. Improved method for predicting linear B-cell epitopes. Immunome Res. 2006;2:2.

21. Jespersen MC, Peters B, Nielsen M, Marcatili P. BepiPred-2.0: improving sequence-based B-cell epitope prediction using conformational epitopes. Nucleic Acids Res. 2017;45(W1):W24-9.

22. Clifford JN, Høie MH, Deleuran S, Peters B, Nielsen M, Marcatili P. BepiPred-3.0: improved B-cell epitope prediction using protein language models. Protein Sci. 2022;31(12):e4497.

23. Benjamin DC, Berzofsky JA, East IJ, Gurd FR, Hannum C, Leach SJ, et al. The antigenic structure of proteins: a reappraisal. Annu Rev Immunol. 1984;2:67-101.

24. Ponomarenko J, Bui HH, Li W, Fusseder N, Bourne PE, Sette A, et al. ElliPro: a new structure-based tool for the prediction of antibody epitopes. BMC Bioinformatics. 2008;9:514.

25. Kringelum JV, Lundegaard C, Lund O, Nielsen M. Reliable B cell epitope predictions: impacts of method development and improved benchmarking. PLoS Comput Biol. 2012;8(12):e1002829.

26. Potocnakova L, Bhide M, Pulzova LB. An Introduction to B-Cell Epitope Mapping and In Silico Epitope Prediction. J Immunol Res. 2016;2016:6760830.

27. Jumper J, Evans R, Pritzel A, Green T, Figurnov M, Ronneberger O, et al. Highly accurate protein structure prediction with AlphaFold. Nature. 2021;596(7873):583-9.

28. Mei S, Li F, Leier A, Marquez-Lago TT, Giam K, Croft NP, et al. A comprehensive review and performance evaluation of bioinformatics tools for HLA class I peptide-binding prediction. Brief Bioinform. 2020;21(4):1119-35.

29. Andreatta M, Nielsen M. Gapped sequence alignment using artificial neural networks: application to the MHC class I system. Bioinformatics. 2016;32(4):511-7.

30. Toussaint NC, Kohlbacher O. OptiTope–a web server for the selection of an optimal set of peptides for epitope-based vaccines. Nucleic Acids Res. 2009;37(Web Server issue):W617-22.

31. Schubert B, Kohlbacher O. Designing string-of-beads vaccines with optimal spacers. Genome Med. 2016;8(1):9.

32. Bui HH, Sidney J, Dinh K, Southwood S, Newman MJ, Sette A. Predicting population coverage of T-cell epitope-based diagnostics and vaccines. BMC Bioinformatics. 2006;7:153.

33. Ferguson AL, Mann JK, Omarjee S, Ndung'u T, Walker BD, Chakraborty AK. Translating HIV sequences into quantitative fitness landscapes predicts viral vulnerabilities for rational immunogen design. Immunity. 2013;38(3):606-17.

34. Vita R, Overton JA, Greenbaum JA, Ponomarenko J, Clark JD, Cantrell JR, et al. The immune epitope database (IEDB) 3.0. Nucleic Acids Res. 2015;43(Database issue):D405-12.

35. Dhanda SK, Vita R, Ha B, Grifoni A, Peters B, Sette A. ImmunomeBrowser: a tool to aggregate and visualize complex and heterogeneous epitopes in reference proteins. Bioinformatics. 2018;34(22):3931-3.

36. Single RM, Meyer D, Hollenbach JA, Nelson MP, Noble JA, Erlich HA, et al. Haplotype frequencies and linkage disequilibrium among classical HLA genes. Immunogenetics. 2007;59(1):1-18.

37. Gonzalez-Galarza FF, McCabe A, Santos EJMD, Jones J, Takeshita L, Ortega-Rivera ND, et al. Allele frequency net database (AFND) 2020 update: gold-standard data classification, open access genotype data and new query tools. Nucleic Acids Res. 2020;48(D1):D783-8.

38. Grifoni A, Weiskopf D, Ramirez SI, Mateus J, Dan JM, Moderbacher CR, et al. Targets of T Cell Responses to SARS-CoV-2 Coronavirus in Humans with COVID-19 Disease and Unexposed Individuals. Cell. 2020;181(7):1489-501.

39. Ahmed SF, Quadeer AA, McKay MR. Preliminary identification of potential vaccine targets for the COVID-19 coronavirus (SARS-CoV-2) based on SARS-CoV immunological studies. Viruses. 2020;12(3):254.

40. Ioannidis JP. Why most published research findings are false. PLoS Med. 2005;2(8):e124.

41. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology. 1982;143(1):29-36.

42. Wang P, Sidney J, Dow C, Mothé B, Sette A, Peters B. A systematic assessment of MHC class II peptide binding predictions and evaluation of a consensus approach. PLoS Comput Biol. 2008;4(4):e1000048.

43. Doytchinova IA, Flower DR. In silico identification of supertypes for class II MHCs. J Immunol. 2005;174(11):7085-95.

44. Ducatez MF, Bahl J, Griffin Y, Stigger-Rosser E, Franks J, Barman S, et al. Feasibility of reconstructed ancestral H5N1 influenza viruses for pandemic preparedness. Proc Natl Acad Sci U S A. 2011;108(1):349-54.

45. Greenbaum JA, Kotturi MF, Kim Y, Oseroff C, Vaughan K, Salimi N, et al. Pre-existing immunity against swine-origin H1N1 influenza viruses in the general human population. Proc Natl Acad Sci U S A. 2009;106(48):20365-70.

46. Grifoni A, Sidney J, Zhang Y, Scheuermann RH, Peters B, Sette A. A Sequence Homology and Bioinformatic Approach Can Predict Candidate Targets for Immune Responses to SARS-CoV-2. Cell Host Microbe. 2020;27(4):671-80.

47. Baruah V, Bose S. Immunoinformatics-aided identification of T cell and B cell epitopes in the surface glycoprotein of 2019-nCoV. J Med Virol. 2020;92(5):495-500.

48. Ton AT, Gentile F, Hsing M, Ban F, Cherkasov A. Rapid identification of potential inhibitors of SARS-CoV-2 main protease by deep docking of 1.3 billion compounds. Mol Inform. 2020;39(8):e2000028.

49. Polack FP, Thomas SJ, Kitchin N, Absalon J, Gurtman A, Lockhart S, et al. Safety and Efficacy of the BNT162b2 mRNA Covid-19 Vaccine. N Engl J Med. 2020;383(27):2603-15.

50. Burton DR, Hangartner L. Broadly neutralizing antibodies to HIV and their role in vaccine design. Annu Rev Immunol. 2016;34:635-59.

51. Haynes BF, Gilbert PB, McElrath MJ, Zolla-Pazner S, Tomaras GD, Alam SM, et al. Immune-correlates analysis of an HIV-1 vaccine efficacy trial. N Engl J Med. 2012;366(14):1275-86.

52. Gaschen B, Taylor J, Yusim K, Foley B, Gao F, Lang D, et al. Diversity considerations in HIV-1 vaccine selection. Science. 2002;296(5567):2354-60.

53. Backert L, Kohlbacher O. Immunoinformatics and epitope prediction in the age of genomic medicine. Genome Med. 2015;7:119.

54. Zhao W, Sher X. Systematically benchmarking peptide-MHC binding predictors: From synthetic to naturally processed epitopes. PLoS Comput Biol. 2018;14(11):e1006457.

55. Nielsen M, Andreatta M, Peters B, Buus S. Immunoinformatics: predicting peptide-MHC binding. Annu Rev Biomed Data Sci. 2020;3:191-215.

56. Kim Y, Ponomarenko J, Zhu Z, Tamang D, Wang P, Greenbaum J, et al. Immune epitope database analysis resource. Nucleic Acids Res. 2012;40(Web Server issue):W525-30.

57. La Gruta NL, Gras S, Daley SR, Thomas PG, Rossjohn J. Understanding the drivers of MHC restriction of T cell receptors. Nat Rev Immunol. 2018;18(7):467-78.

58. Yewdell JW, Antón LC, Bennink JR. Defective ribosomal products (DRiPs): a major source of antigenic peptides for MHC class I molecules? J Immunol. 1996;157(5):1823-6.

59. Kloetzel PM. Antigen processing by the proteasome. Nat Rev Mol Cell Biol. 2001;2(3):179-87.

60. Davis MM, Boyd SD. Recent progress in the analysis of αβT cell and B cell receptor repertoires. Curr Opin Immunol. 2019;59:109-14.

61. Madi A, Shifrut E, Reich-Zeliger S, Gal H, Best K, Ndifon W, et al. T-cell receptor repertoires share a restricted set of public and abundant CDR3 sequences that are associated with self-related immunity. Genome Res. 2014;24(10):1603-12.

62. Yewdell JW, Bennink JR. Immunodominance in major histocompatibility complex class I-restricted T lymphocyte responses. Annu Rev Immunol. 1999;17:51-88.

63. Kotturi MF, Scott I, Wolfe T, Peters B, Sidney J, Cheroutre H, et al. Naive precursor frequencies and MHC binding rather than the degree of epitope diversity shape CD8+ T cell immunodominance. J Immunol. 2008;181(3):2124-33.

64. Sidney J, Peters B, Frahm N, Brander C, Sette A. HLA class I supertypes: a revised and updated classification. BMC Immunol. 2008;9:1.

65. Thorsby E. Invited anniversary review: HLA associated diseases. Hum Immunol. 1997;53(1):1-11.

66. Trowsdale J, Knight JC. Major histocompatibility complex genomics and human disease. Annu Rev Genomics Hum Genet. 2013;14:301-23.

67. Dawkins R, Leelayuwat C, Gaudieri S, Tay G, Hui J, Cattley S, et al. Genomics of the major histocompatibility complex: haplotypes, duplication, retroviruses and disease. Immunol Rev. 1999;167:275-304.

68. Hill AV. Aspects of genetic susceptibility to human infectious diseases. Annu Rev Genet. 2006;40:469-86.

69. DiMasi JA, Grabowski HG, Hansen RW. Innovation in the pharmaceutical industry: New estimates of R&D costs. J Health Econ. 2016;47:20-33.

70. Pronker ES, Weenen TC, Commandeur H, Claassen EHJHM, Osterhaus ADME. Risk in vaccine research and development quantified. PLoS One. 2013;8(3):e57755.

71. Light DW, Lexchin JR. Pharmaceutical research and development: what do we get for all that money? BMJ. 2012;345:e4348.

72. Kremer M, Levin J, Snyder CM. Advance market commitments: insights from theory and experience. American Economic Review. 2020;110(2):439-68.

73. Patronov A, Doytchinova I. T-cell epitope vaccine design by immunoinformatics. Open Biol. 2013;3(1):120139.

74. Russell CA, Jones TC, Barr IG, Cox NJ, Garten RJ, Gregory V, et al. The global circulation of seasonal influenza A (H3N2) viruses. Science. 2008;320(5874):340-6.

75. Ott PA, Hu Z, Keskin DB, Shukla SA, Sun J, Bozym DJ, et al. An immunogenic personal neoantigen vaccine for patients with melanoma. Nature. 2017;547(7662):217-21.

76. Keskin DB, Anandappa AJ, Sun J, Tirosh I, Mathewson ND, Li S, et al. Neoantigen vaccine generates intratumoral T cell responses in phase Ib glioblastoma trial. Nature. 2019;565(7738):234-9.

77. Aalberse RC, Akkerdaas J, van Ree R. Cross-reactivity of IgE antibodies to allergens. Allergy. 2001;56(6):478-90.

78. Rappuoli R. Reverse vaccinology, a genome-based approach to vaccine development. Vaccine. 2001;19(17-19):2688-91.

79. McMichael AJ, Koff WC. Vaccines that stimulate T cell immunity to HIV-1: the next step. Nat Immunol. 2014;15(4):319-22.

80. Richman DD, Wrin T, Little SJ, Petropoulos CJ. Rapid evolution of the neutralizing antibody response to HIV type 1 infection. Proc Natl Acad Sci U S A. 2003;100(7):4144-9.

81. Krammer F, García-Sastre A, Palese P. Is it possible to develop a “universal” influenza virus vaccine? Toward a universal influenza virus vaccine: potential target antigens and critical aspects for vaccine development. Cold Spring Harb Perspect Biol. 2018;10(7):a028845.

82. Steel J, Lowen AC, Wang TT, Yondola M, Gao Q, Haye K, et al. Influenza virus vaccine based on the conserved hemagglutinin stalk domain. mBio. 2010;1(1):e00018-10.

83. Floreani A, Restrepo-Jiménez P, Secchi MF, De Martin S, Leung PSC, Krawitt E, et al. Etiopathogenesis of autoimmune hepatitis. J Autoimmun. 2018;95:133-43.

84. Sette A, Rappuoli R. Reverse vaccinology: developing vaccines in the era of genomics. Immunity. 2010;33(4):530-41.

85. Peters B, Nielsen M, Sette A. T Cell Epitope Predictions. Annu Rev Immunol. 2020;38:123-45.

86. Sanchez-Trincado JL, Gomez-Perosanz M, Reche PA. Fundamentals and Methods for T- and B-Cell Epitope Prediction. J Immunol Res. 2017;2017:2680160.

87. Flower DR, Macdonald IK, Ramakrishnan K, Davies MN, Doytchinova IA. Computer aided selection of candidate vaccine antigens. Immunome Res. 2010;6(Suppl 2):S1.

88. He Y, Rappuoli R, De Groot AS, Chen RT. Emerging vaccine informatics. J Biomed Biotechnol. 2010;2010:218590.

89. Lundegaard C, Lund O, Nielsen M. Prediction of epitopes using neural network based methods. J Immunol Methods. 2011;374(1-2):26-34.

90. De Groot AS, Moise L, Terry F, Gutman J, Hindocha P, Richard G, et al. Better epitope discovery, precision immune engineering, and accelerated vaccine design using immunoinformatics tools. Front Immunol. 2020;11:442.

91. Malonis RJ, Lai JR, Vergnolle O. Peptide-based vaccines: current progress and future challenges. Chem Rev. 2020;120(6):3210-29.

92. Davies MN, Flower DR. Harnessing bioinformatics to discover new vaccines. Drug Discov Today. 2007;12(9-10):389-95.

93. Flower DR. Bioinformatics for vaccinology. John Wiley & Sons; 2008.

94. Tomar N, De RK. Immunoinformatics: a brief review. Methods Mol Biol. 2014;1184:23-55.

95. Singh H, Raghava GP. ProPred1: prediction of promiscuous MHC Class-I binding sites. Bioinformatics. 2003;19(8):1009-14.

96. Rock KL, Reits E, Neefjes J. Present yourself! By MHC class I and MHC class II molecules. Trends Immunol. 2016;37(11):724-37.

97. Schumacher TN, Schreiber RD. Neoantigens in cancer immunotherapy. Science. 2015;348(6230):69-74.

98. Oyarzun P, Ellis JJ, Bodén M, Kobe B. PREDIVAC: CD4+ T-cell epitope prediction for vaccine design that covers 95% of HLA class II DR protein diversity. BMC Bioinformatics. 2013;14:52.

99. Bonsack M, Hoppe S, Winter J, Tichy D, Zeller C, Küpper MD, et al. Performance Evaluation of MHC Class-I Binding Prediction Tools Based on an Experimentally Validated MHC-Peptide Binding Data Set. Cancer Immunol Res. 2019;7(5):719-36.

100. Dhanda SK, Mahajan S, Paul S, Yan Z, Kim H, Jespersen MC, et al. IEDB-AR: immune epitope database-analysis resource in 2019. Nucleic Acids Res. 2019;47(W1):W502-6.

Word count: 4,847 words
Figures: 2 conceptual diagrams
References: 100 (Vancouver style)

Target: PLOS Computational Biology Review Article
Format: Complete submission-ready manuscript